PEG2000-C-DMG|LNP |DC Chemicals

Cas No.:	1019000-64-6
Chemical Name:	PEG2000C-DMG
SMILES:	CCCCCCCCCCCCCCOCC(OCCCCCCCCCCCCCC)COC(=O)NCCCO{-}CC{+n}OC
Formula:	C₃₆H₇₃NO₅(C₂H₄O)N
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	1. Hobo, W., Novobrantseva, T., Fredrix, H., et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol. Immunother. 62(2), 285-297 (2013).

Description:

PEG(2000)-C-DMG represents a PEGylated derivative synthesized from 1,2-dimyristoyl-sn-glycerol (1,2-DMG). This compound is instrumental in the formulation of lipid nanoparticles (LNPs), particularly when combined with other lipidic compounds, for the efficient delivery of small interfering RNA (siRNA). Specifically, LNPs incorporating PEG(2000)-C-DMG and encapsulating siRNA designed to target the genes responsible for encoding programmed cell death protein ligand 1 (PD-L1) and PD-L2 have demonstrated efficacy in reducing the expression levels of PD-L1 and PD-L2 in monocyte-derived dendritic cells. Furthermore, formulations that include PEG(2000)-C-DMG are being actively explored in the advancement of LNPs aimed at the delivery of siRNA-based vaccines, highlighting its critical role in the development of therapeutic and prophylactic strategies.

References:

1. Hobo, W., Novobrantseva, T., Fredrix, H., et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol. Immunother. 62(2), 285-297 (2013).

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC58047	DSPE-PEG 2000	PEG2000-DSPE is used for creating micelles that are able to carry drugs with low solubility.
DC67161	MPEG-2000-DPPE Na	DPPE-MPEG(2000) is a PEGylated form of 1,2-dipalmitoyl-rac-glycero-3-PE (DPPE). It has been used in the synthesis of anionic liposomes for drug redistribution and toxicity prevention.
DC49193	PEG2000-C-DMG	PEG(2000)-C-DMG represents a PEGylated derivative synthesized from 1,2-dimyristoyl-sn-glycerol (1,2-DMG). This compound is instrumental in the formulation of lipid nanoparticles (LNPs), particularly when combined with other lipidic compounds, for the efficient delivery of small interfering RNA (siRNA). Specifically, LNPs incorporating PEG(2000)-C-DMG and encapsulating siRNA designed to target the genes responsible for encoding programmed cell death protein ligand 1 (PD-L1) and PD-L2 have demonstrated efficacy in reducing the expression levels of PD-L1 and PD-L2 in monocyte-derived dendritic cells. Furthermore, formulations that include PEG(2000)-C-DMG are being actively explored in the advancement of LNPs aimed at the delivery of siRNA-based vaccines, highlighting its critical role in the development of therapeutic and prophylactic strategies.